LIFE - aTyr Pharma Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

aTyr Pharma's ([[LIFE]] +1.5%) partner Kyorin Pharmaceutical has completed the last subject visit in its Phase 1 trial of aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan). The event triggered milestone payment to aTyr.The Phase 1 trial, will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in 32 healthy male volunteers. Results from this study are intended to enable Kyorin to initiate patient trials in interstitial lung disease (ILD) in Japan.Kyorin is aTyr’s partner for the development and commercialization of ATYR1923 for ILDs in Japan.

For further details see:

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan